Roche Sees Cancer Combos Start To Deliver

Roche presented a strong second quarter and was able to highlight a positive debut of Tecentriq, its PD-L1 antagonist, which brought the Swiss group into the lauded programed-death checkpoint inhibitor field.

Schwan_Severin_1200x675
CEO Severin Schwan • Source: Roche

Roche said group sales increased 5% to CHF25bn in the six months to June 30, slightly ahead of expectations. Net income rose by 3% at constant currencies to CHF5.5bn. Pharmaceutical sales were up by 4% to CHF19.5bn, driven by oncology and immunology drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By 

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By 

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

More from Scrip

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By 

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.